Xenon Pharmaceuticals Inc. XENE
At closeNov 11, 2026, 4:00 AM EST
Pre-market · Nov 11, 4:00 AM ET
- YTD
- -7.65%
- 1 year
- +7.76%
- Market cap
- 4.01B
- EPS (ttm)
- -4.69
- Shares out
- 96.84M
- Forward P/E
- -8.87
- YTD return
- -7.65%
- 1-year return
- +7.76%
- Volume
- 2.09M
- Avg volume
- 1.59M
- Open
- 40.49
- Previous close
- 40.45
- Day's range
- 40.09 – 41.48
- 52-week range
- 33.38 – 72.66
- Analysts
- Strong Buy
- Price target
- 71.75 (+73.4%)
- Earnings date
- Feb 25, 2027
5D +2.16 (+5.51%)
Key statistics
- Enterprise value
- 3.03B
- PEG ratio
- 0.00
- Price / book
- 3.55
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -219.89M
- Total cash
- 950.80M
- Total debt
- 6.01M
- Return on equity
- -50.27%
- Short % of float
- 7.60%
- 50-day average
- 42.64
- 200-day average
- 52.29
Analyst view
Consensus: strong buy
- Target (low)
- 46.00
- Target (mean)
- 71.75
- Target (high)
- 90.00
- Strong buy3
- Buy14
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -1.15.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -1.16 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -1.13 | -1.11 | +0.02 | +1.77% |
| Aug 6, 2026 | Jun 30, 2026 | -1.14 | -1.11 | +0.03 | +2.63% |
| May 7, 2026 | Mar 31, 2026 | -1.17 | -1.17 | 0.00 | 0.00% |
| Feb 26, 2026 | Dec 31, 2025 | -1.20 | -1.31 | -0.11 | -9.17% |
| Nov 3, 2025 | Sep 30, 2025 | -1.16 | -1.15 | +0.01 | +0.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 18, 2026 | Wedbush | main | Outperform | Outperform |
| Sep 18, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 18, 2026 | Deutsche Bank | down | Buy | Hold |
| Sep 18, 2026 | Needham | main | Buy | Buy |
| Sep 18, 2026 | Baird | main | Outperform | Outperform |
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- xenon-pharma.com
News
Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript 
Xenon Pharmaceuticals Q3 Earnings Call Highlights 
Xenon Pharmaceuticals Q3 2026 Earnings Call Transcript 
Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) Estimate 
Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association For The Study Of Pain 2026 World Congress On Pain 
Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call
Your note
Sign in to keep a note on XENE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CANNON GILLIAN | Director | Sale | Jun 4, 2026 | 1,455 |
| DIFABIO ANDREA | Officer | Sale | Mar 12, 2026 | 7,301 |
| GANNON STEVEN | Director | Sale | Aug 10, 2026 | 1,870 |
| GAROFALO ELIZABETH AMY M.D. | Director | Conversion of Exercise of derivative security | May 31, 2026 | 2,645 |
| GOVER JUSTIN DAVID | Director | Conversion of Exercise of derivative security | May 31, 2026 | 2,645 |
| KELLY THOMAS PATRICK | Chief Financial Officer | Purchase | Sep 29, 2026 | 15,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 9.98% | 9,647,998 | 399.33M | Jun 29, 2026 |
| Blackrock Inc. | 7.78% | 7,522,482 | 311.36M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.98% | 5,777,777 | 239.14M | Jun 29, 2026 |
| Polar Capital Holdings PLC | 4.73% | 4,570,556 | 189.18M | Jun 29, 2026 |
| Driehaus Capital Management, LLC | 4.57% | 4,418,557 | 182.88M | Jun 29, 2026 |
| Jupiter Topco LLC | 4.33% | 4,186,519 | 173.28M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 3.71% | 3,583,633 | 148.33M | Sep 29, 2026 |
| SmallCap World Fund Inc | 2.91% | 2,814,992 | 116.51M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.63% | 2,537,750 | 105.04M | Sep 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 1.32% | 1,274,673 | 52.76M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.11% | 1,074,458 | 44.47M | Aug 30, 2026 |
| JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.00% | 962,101 | 39.82M | Jun 29, 2026 |